The metabolism and pharmacokinetics of aztreonam (SQ 26,776) were studied in four healthy male volunteers, each of whom received single 500-mg intravenous and intramuscular doses of "4C-labeled drug according to a two-way crossover design. Serial The purpose of this study was to investigate further the metabolism and pharmacokinetics of aztreonam by using, for the first time, the radiolabeled drug administered both intravenously and intramuscularly to the same subjects.
The monobactam aztreonam, in single-dose studies in healthy male volunteers, displays linear kinetics, as determined by microbiological and high-pressure liquid chromatography assays over an intravenous dose range of 125 to 4,000 mg and an intramuscular dose range of 250 to 1,000 mg, with a terminal half-life of between 1.3 and 2 h (10) . Multiple intravenous and intramuscular 500-and 1,000-mg doses, administered every 8 h resulted in no significant change in pharmacokinetic parameters. Serum protein binding of aztreonam averages 56%. SQ 26,992 is a microbiologically inactive biotransformation product of aztreonam and is formed in humans by the hydrolytic opening of the beta-lactam ring of aztreonam, as determined by high-pressure liquid chromatography (9) .
The purpose of this study was to investigate further the metabolism and pharmacokinetics of aztreonam by using, for the first time, the radiolabeled drug administered both intravenously and intramuscularly to the same subjects.
MATERIALS AND METHODS
Subjects. Six healthy male subjects participated in this study; however, urine collections for two were incomplete. The latter two subjects were excluded from any further consideration in this report. The four remaining subjects had a mean age of 28 years (range, 21 to 30), mean height of 177 cm (range, 168 to 187), and mean weight of 73.3 kg (range, 69.2 to 80.1). All four subjects were considered healthy as determined by normal physical examination, 12-lead electrocardiogram, complete blood count, urinalysis, and serum chemistry proffle. None had a history of chronic disease, drug abuse, recent drug ingestion, or allergy to any drug or other substances. All of the subjects gave informed, written consent before entry into this study. The study protocol was approved by the Insti- . Counting efficiency was determined with automatic external standardization and the use of previously prepared quench curves. The quantitation limit for total radioactivity in serum, PFF, and urine was 0.2 Fg/ml; the limit in feces was 1 pg/g. (5 g) were extracted five times with 8 ml of methanol. Portions (1.0 ml) of the combined methanolic extracts were assayed by thin-layer radiochromatography (TLRC) for total radioactivity. The remainder of each extract was filtered through glass wool and evaporated to dryness in vacuo at about 25°C. The residue then was reconstituted in 0.6 ml of methanol.
TLRC. Homogenates of feces
Samples of urine (25 pl) and the reconstituted methanolic extracts offeces (100 ,ul) were chromatographed on 0.25-mm silica gel GF plates (Analtech, Inc., New 
RESULTS
The mean concentrations of total radioactivity in serum are shown in Table 1 for four subjects receiving both intravenous and intramuscular doses of aztreonam. The initial concentrations of total radioactivity immediately after intravenous administration were higher than those after intramuscular administration, as might be expected. However, between 2 and 12 h, the concentrations of total radioactivity were generally higher for intramuscular than for intravenous administration. The 1-and 1.5-h concentrations were similar for both routes of administration. The terminal elimination phase for the total radioactivity in serum was nonlinear for individual subjects; this may have been due to differing rates of formation or elimination of aztreonam and its metabolites (not quantitated in serum by radiochemical assay). The mean concentrations of aztreonam in serum, as measured by bioassay, are shown in Table 1 . After intravenous administration, the decline of aztreonam levels in serum was biphasic over a 1,000-fold range of concentrations in serum. After intramuscular administration, levels of aztreonam in serum displayed first-order ascending-absorption and descending-elimination phases.
The pharmacokinetic parameter values are summarized in Table 2 . Based on a comparison of serum AUC values for unchanged aztreonam after intravenous and intramuscular administration, the absolute bioavailability of aztreonam after intramuscular administration was 101 + 3%. Absorption of aztreonam from the intramuscular injection site was also rapid (t1/2a = 0.42 h).
The apparent volume of distribution (Varca) was the same for both routes of administration. The extent of urinary aztreonam elimination over 6 days for intravenous and intramuscular dosing was 67 and 64%, respectively. Values for serum and renal cleaPance were also similar, and the terminal half-life was 1.6 and 1.7 h for intravenous and intramuscular administrations, respectively.
Serum protein binding based on total radioactivity was independent of sampling time and averaged 69.5 and 71.7% after intravenous and intramuscular dosing, respectively.
The time course of mean urinary and fecal excretion of total radioactivity is shown in Fig. 1 for both routes of drug administration. Urinary and fecal excretion was essentially complete by 12 and 48 h after dosing, respectively. Figure 2 shows the time course of mean cumulative aztreonam and SQ 26,992 excretion in urine, as assayed by TLRC methods. Table 3 ably, indicating the absence of bioactive metabolites of the monobactam. The aztreonam concentration in pooled fecal specimens for all subjects between 24 and 96 h after dosing was in the range of 10 to 20 pug/gm of feces. Table 4 summarizes recovery of total radioactivity in urine and feces and the components of total radioactivity, i.e., aztreonam, SQ 26,992, and unknown (extractable and nonextractable) metabolites.
There 'were no important differences in biotransfomation profil6s and recoveries of total radioactivity for the two routes of admitiistration. Approximately 90%6 of the total dose was accounted for. Aztreonam and SQ 26,992 in urine represented a mean of about 66 and 7%6 of the dose, respectively, and in feces, about 1 significantly affected by the presence of human serum (6) .
The apparent half-life of the elimination of SQ 26,992 was more than 10 times that of aztreonam, based on urinary excretion data. Slow formation or elimination of SQ 26,992 may account for much of the total serum radioactivity measured 4 h or more after dosing. Unfortunate 
